Carly Whyte is an early-career researcher with expertise in the cellular and molecular mechanisms underlying immune-mediated pathology. Her research focuses on understanding how our immune systems can recognise and respond to cancer, with a view towards developing new immunotherapies for patients with solid tumours. She is supported by a Passe and Williams Junior Fellowship.
Dr Whyte holds a PhD in Immunology from the University of Adelaide, during which she discovered a previously unknown regulator of immune cell migration into tumours called ACKR4. She was then appointed as a postdoctoral research scientist at the Babraham Institute, Cambridge, UK and a Research Associate at Fitzwilliam College, University of Cambridge. During this... Read more
About me
Carly Whyte is an early-career researcher with expertise in the cellular and molecular mechanisms underlying immune-mediated pathology. Her research focuses on understanding how our immune systems can recognise and respond to cancer, with a view towards developing new immunotherapies for patients with solid tumours. She is supported by a Passe and Williams Junior Fellowship.
Dr Whyte holds a PhD in Immunology from the University of Adelaide, during which she discovered a previously unknown regulator of immune cell migration into tumours called ACKR4. She was then appointed as a postdoctoral research scientist at the Babraham Institute, Cambridge, UK and a Research Associate at Fitzwilliam College, University of Cambridge. During this postdoctoral training with Prof. Adrian Liston, Dr Whyte elucidated signaling networks of the cytokine IL-2, discovering novel mechanisms of action for this protein and identifying new regulatory networks which explained some of the common side-effects of therapeutic use of IL-2.
About me
Doctor of Philosophy University of Adelaide
Bachelor of Science (Honours) University of Adelaide
Bachelor of Science (Biomedical Science) University of Adelaide
Research
Excludes commercial-in-confidence projects.
Overcoming immune exhaustion in recurrent head and neck cancer, Garnett Passe & Rodney Williams Memorial Foundation-Conjoint Grant, 01/01/2025 - 31/12/2027
Defining the therapeutic potential of eosinophils in melanoma, Australian Melanoma Research Foundation, 01/02/2025 - 31/01/2026
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID or Scopus
Open access indicates that an output is open access.
Year | Output |
---|---|
2023 |
Open access
9
9
85
|
2022 |
Open access
20
23
76
|
2022 |
Open access
16
15
197
|
2022 |
Open access
90
88
282
|
2021 |
Open access
23
22
43
|
2021 |
Open access
25
23
32
|
2020 |
Open access
35
36
203
|
2020 |
Open access
205
198
298
|
2020 |
Open access
28
27
17
|
2019 |
Open access
74
74
23
|
2018 |
Open access
20
19
13
|
2017 |
Open access
25
26
1
|
2017 |
Open access
94
90
15
|
2015 |
Open access
104
101
92
|
External engagement & recognition
Organisation | Country |
---|---|
Australian National University | AUSTRALIA |
Babraham Institute | UNITED KINGDOM |
Benaroya Research Institute | UNITED STATES |
Catholic University of Leuven | BELGIUM |
FlowJo (United States) | UNITED STATES |
Free University of Amsterdam | NETHERLANDS |
Ku Leuven | BELGIUM |
Monash University | AUSTRALIA |
QIMR Berghofer Medical Research Institute | AUSTRALIA |
University Hospital Regensburg | GERMANY |
University of Adelaide | AUSTRALIA |
University of Cambridge | UNITED KINGDOM |
University of Melbourne | AUSTRALIA |
University of Queensland | AUSTRALIA |
University of Rochester Medical Center | UNITED STATES |
University of South Australia | AUSTRALIA |
University of Washington | UNITED STATES |
VIB Bioinformatics Core | BELGIUM |
VIB-KU Leuven Center for Brain & Disease Research | BELGIUM |
Walter and Eliza Hall Institute of Medical Research | AUSTRALIA |
Wellcome Sanger Institute | UNITED KINGDOM |